Advanced Cell Diagnostics Secures $22M Series C

June 19, 2015

Share:

Advanced Cell Diagnostics, a developer of cell- and tissue-based diagnostic tests for precision medicine, has raised a $22 million Series C financing led by Summit Partners, with participation from Kenson Ventures and existing investors Morningside Ventures and New Leaf Venture Partners. Proceeds from the investment will be used in part to launch a new technology based on the company's RNAscope tech, which provides molecular and morphological information in a single assay to maximize the clinical utility of RNA biomarkers.